Changes in CDKN2A/2B expression associate with T-cell phenotype modulation in atherosclerosis and type 2 diabetes mellitus.

Animals Atherosclerosis / metabolism Diabetes Mellitus, Type 2 / metabolism Genes, p16 Humans Leukocytes, Mononuclear Male Mice Mice, Knockout, ApoE Neointima

Journal

Translational research : the journal of laboratory and clinical medicine
ISSN: 1878-1810
Titre abrégé: Transl Res
Pays: United States
ID NLM: 101280339

Informations de publication

Date de publication:
01 2019
Historique:
received: 23 03 2018
revised: 03 08 2018
accepted: 07 08 2018
pubmed: 4 9 2018
medline: 8 3 2019
entrez: 4 9 2018
Statut: ppublish

Résumé

Previous studies indicate a role of CDKN2A/2B/2BAS genes in atherosclerosis and type 2 diabetes mellitus (T2DM). Progression of these diseases is accompanied by T-cell imbalance and chronic inflammation. Our main objective was to investigate a potential association between CDKN2A/2B/2BAS gene expression and T cell phenotype in T2DM and coronary artery disease (CAD) in humans, and to explore the therapeutic potential of these genes to restore immune cell homeostasis and disease progression. Reduced mRNA levels of CDKN2A (p16

Identifiants

DOI: 10.1016/j.trsl.2018.08.003 PMID: 30176239
pubmed: 30176239
pii: S1931-5244(18)30138-5
doi: 10.1016/j.trsl.2018.08.003
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

31-48

Informations de copyright

Copyright © 2018. Published by Elsevier Inc.

Auteurs

Ángela VinuÉ (Á)

Institute of Health Research-INCLIVA, Valencia, Spain.

Sergio MartÍnez-HervÁs (S)

Institute of Health Research-INCLIVA, Valencia, Spain; Endocrinology and Nutrition Department Hospital Clínico Universitario. Department of Medicine, University of Valencia, Valencia, Spain; CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.

Andrea Herrero-Cervera (A)

Institute of Health Research-INCLIVA, Valencia, Spain.

Verónica SÁnchez-GarcÍa (V)

Institute of Health Research-INCLIVA, Valencia, Spain.

Irene AndrÉs-Blasco (I)

Institute of Health Research-INCLIVA, Valencia, Spain.

Laura Piqueras (L)

Institute of Health Research-INCLIVA, Valencia, Spain.

MarÍa JesÚs Sanz (MJ)

Institute of Health Research-INCLIVA, Valencia, Spain; Department of Pharmacology, University of Valencia, Valencia, Spain.

JosÉ TomÁs Real (JT)

Institute of Health Research-INCLIVA, Valencia, Spain; Endocrinology and Nutrition Department Hospital Clínico Universitario. Department of Medicine, University of Valencia, Valencia, Spain; CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.

Juan F Ascaso (JF)

Institute of Health Research-INCLIVA, Valencia, Spain; Endocrinology and Nutrition Department Hospital Clínico Universitario. Department of Medicine, University of Valencia, Valencia, Spain; CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.

Deborah Jane Burks (DJ)

CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain; Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain.

Herminia GonzÁlez-Navarro (H)

Institute of Health Research-INCLIVA, Valencia, Spain; CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: herminia.gonzalez@uv.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Changes in CDKN2A/2B expression associate with...
questionsmedicales.fr › Maladies cardiovasculaires › Maladies vasculaires › Artériopathies oblitérantes › Artériosclérose › Athérosclérose › Changes in CDKN2A/2B expression associate with...
questionsmedicales.fr › Maladies endocriniennes › Diabète › Diabète de type 2 › Changes in CDKN2A/2B expression associate with...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Gènes suppresseurs de tumeur › Gènes p16 › Changes in CDKN2A/2B expression associate with...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Changes in CDKN2A/2B expression associate with...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Changes in CDKN2A/2B expression associate with...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Changes in CDKN2A/2B expression associate with...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souris transgéniques › Souris knockout › Souris invalidées pour les gènes ApoE › Changes in CDKN2A/2B expression associate with...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Néointima › Changes in CDKN2A/2B expression associate with...